Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Clinical trial NCT05232916 · RECRUITING
Trial details
- NCT number
- NCT05232916
- Sponsor
- Greenwich LifeSciences, Inc.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-16
- Primary completion
- 2031-12-01
- Enrollment
- 2250
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.